Kodiak Sciences enters the final stretch of September with a notable divergence: most of its institutional holders remain constructive, Goldman Sachs just re-entered coverage with a cautious stance, and short sellers are quietly rebuilding positions into an 18% monthly decline.
Goldman's reinstatement is the week's clearest signal shift. The firm's analyst Andrea Newkirk reinstated coverage on September 24 with a Neutral rating and a $36 target — just $3.70 above the current price of $32.35. That's a far cry from the bullish targets clustered across the rest of the Street. HC Wainwright holds a $58 Buy, JPMorgan sits at $66 Overweight, and UBS carries an $80 Buy. Goldman's $36 effectively marks the floor of the range, and its reappearance at Neutral rather than Buy is a meaningful anchor on sentiment. The consensus technically reads "hold," with the mean target at $64 — nearly double the current price — but Goldman's conservative entry point suggests not everyone on the Street shares that confidence.
Short interest tells a steady, grinding story rather than an aggressive one. Bears hold roughly 20.2% of the free float short — elevated, but not extreme by biotech standards. That position has crept up about 9% over the past month, with the most recent daily read showing 10.7 million shares short. The drift is gradual rather than a sudden conviction trade. Borrowing costs remain low at 0.55%, and availability is well above normal at 678% — for every share already borrowed, more than six remain in the pool. The borrow market is not under stress. Options positioning is similarly relaxed: the put/call ratio of 1.09 sits only a quarter of a standard deviation above its 20-day average, close to neutral. Neither the lending market nor the options market is signaling acute bearish pressure — the short side is building slowly, not piling in.
The ownership picture is dominated by one name: Baker Bros. Advisors, with 31.8% of shares and an active Schedule 13D on the register filed in December 2025. An activist at nearly a third of the company is among the most consequential structural facts about this stock. Baker Bros. has not changed its position recently, but the 13D designation signals engagement beyond passive ownership. T. Rowe Price added 1.85 million shares in its most recent report, and BlackRock and State Street both added modestly. Point72, notably, filed a 13G amendment cutting its stake from 3.5% to 1.0% — a meaningful reduction from one of the sharper-elbowed funds in biotech. (All 13D/G positions are as last disclosed around the 5% threshold; holders dropping below 5% may exit without a further filing.)
The bull case rests on the ABC platform — tarcocimab tedromer showing over 90% retinal dryness rates in the KSI-101 trial, with meaningful vision gains and rising probabilities of success for both diabetic retinopathy and wet AMD. The bear case is the company's clinical history: the GLEAM, GLIMMER, and DAZZLE trial failures haven't been forgotten. The ORTEX short score of 68.8 has been remarkably stable all week, oscillating in a tight range with no directional break. EPS momentum scores rank in the 75th–77th percentiles, suggesting estimates are moving in the right direction, though the company remains deeply loss-making: price-to-book runs at 10.6x on a negative earnings base, and EV/EBITDA is meaningfully negative.
Earnings are next due November 12. Kodiak's last four prints have landed negatively on a five-day basis in three of four cases, with the worst five-day move a 15.8% decline following the June 2 report. What to watch between now and then: whether Goldman's $36 target proves a gravitational pull for the stock, whether the gradual short-interest build accelerates as the print approaches, and whether Baker Bros. files any amendment that signals a change in its engagement posture.
See the live data behind this article on ORTEX.
Open KOD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
